NAS:ENTA (USA) Also trade in: Germany

Enanta Pharmaceuticals Inc

$ 85.81 -11.54 (-11.85%)
Volume: 721,020 Avg Vol (1m): 192,453
Market Cap $: 1.69 Bil Enterprise Value $: 1.32 Bil
P/E (TTM): 23.10 P/B: 4.15
Earnings Power Value 24.79
Net Current Asset Value 18.9
Tangible Book 20.69
Projected FCF 45.89
Median P/S Value 88.99
Graham Number 41.61
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1486.57
Cash-To-Debt ranked higher than
78.66% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ENTA: 1486.57
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 242.82, Med: 1275.97, Max: 10000
Current: 1486.57
242.82
10000
Equity-to-Asset 0.95
Equity-to-Asset ranked higher than
94.63% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ENTA: 0.95
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -2.03, Med: 0.95, Max: 0.96
Current: 0.95
-2.03
0.96
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 46.59
DISTRESS
GREY
SAFE
Beneish M-Score -2.77
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 90.4%
WACC 11.49%

Profitability & Growth : 9/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 35.75
Operating Margin ranked higher than
96.84% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ENTA: 35.75
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 23.94, Med: 39.77, Max: 77.17
Current: 35.75
23.94
77.17
Net Margin % 33.28
Net Margin ranked higher than
94.44% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ENTA: 33.28
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 17.23, Med: 34.82, Max: 72.14
Current: 33.28
17.23
72.14
ROE % 19.95
ROE ranked higher than
95.05% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ENTA: 19.95
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -8.51, Med: 11.41, Max: 41.05
Current: 19.95
-8.51
41.05
ROA % 18.86
ROA ranked higher than
96.68% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ENTA: 18.86
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 5.83, Med: 22.36, Max: 178.65
Current: 18.86
5.83
178.65
ROC (Joel Greenblatt) % 152.34
ROC (Joel Greenblatt) ranked higher than
97.10% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ENTA: 152.34
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 132.61, Med: 503.76, Max: 9914.23
Current: 152.34
132.61
9914.23
3-Year Total Revenue Growth Rate 8.70
3-Year Revenue Growth Rate ranked higher than
81.72% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ENTA: 6.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -46.1, Med: 9.1, Max: 28.7
Current: 6.3
-46.1
28.7
3-Year Total EBITDA Growth Rate -10.40
3-Year EBITDA Growth Rate ranked higher than
61.97% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ENTA: -12.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -53.6, Med: 1.6, Max: 19.8
Current: -12.4
-53.6
19.8
3-Year EPS w/o NRI Growth Rate -5.20
3-Year EPS w/o NRI Growth Rate ranked lower than
75.62% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ENTA: -5.2
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -12.75, Max: 39.4
Current: -5.2
0
39.4

» ENTA's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ENTA

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2835
Compare SZSE:002287 NAS:BOLD NAS:ARWR BOM:539268 NAS:XNCR NAS:MDGL NAS:ZGNX OCSE:ALK B NAS:ALLK NAS:ZLAB NAS:ATRA NAS:ORTX NAS:RGNX SZSE:300294 NAS:RUBY NYSE:CBM XKRX:006280 TSE:4592 NAS:CORT NAS:ALEC
Traded in other countries 9EP.Germany
Address 500 Arsenal Street, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is an American biotechnology company focused on research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are: hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of the company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Ratios

Current vs industry vs history
PE Ratio (TTM) 23.10
PE Ratio ranked higher than
59.27% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
ENTA: 23.1
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 5.17, Med: 21.95, Max: 57.59
Current: 23.1
5.17
57.59
PE Ratio without NRI 23.10
PE without NRI ranked higher than
59.26% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
ENTA: 23.1
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 5.17, Med: 21.95, Max: 57.59
Current: 23.1
5.17
57.59
Price-to-Owner-Earnings 24.19
Price-to-Owner-Earnings ranked lower than
72.41% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
ENTA: 24.19
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 16.64, Med: 36.38, Max: 155.57
Current: 24.19
16.64
155.57
PB Ratio 4.15
PB Ratio ranked lower than
56.03% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ENTA: 4.15
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.55, Med: 3.3, Max: 7.42
Current: 4.15
1.55
7.42
PS Ratio 7.72
PS Ratio ranked higher than
50.55% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ENTA: 7.72
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.32, Med: 7.98, Max: 121.58
Current: 7.72
1.32
121.58
Price-to-Free-Cash-Flow 20.45
Price-to-Free-Cash-Flow ranked lower than
52.63% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
ENTA: 20.45
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 2.47, Med: 20.47, Max: 124.31
Current: 20.45
2.47
124.31
Price-to-Operating-Cash-Flow 19.41
Price-to-Operating-Cash-Flow ranked lower than
60.95% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
ENTA: 19.41
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 2.4, Med: 19.42, Max: 76.05
Current: 19.41
2.4
76.05
EV-to-EBIT 15.78
EV-to-EBIT ranked higher than
64.75% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ENTA: 15.78
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -41.1, Med: 8.1, Max: 42.1
Current: 15.78
-41.1
42.1
EV-to-EBITDA 15.23
EV-to-EBITDA ranked higher than
61.57% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ENTA: 15.23
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -48.8, Med: 7.9, Max: 41.4
Current: 15.23
-48.8
41.4
EV-to-Revenue 5.58
EV-to-Revenue ranked higher than
64.33% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ENTA: 5.58
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -2.2, Med: 7.1, Max: 122.9
Current: 5.58
-2.2
122.9
PEG Ratio 1.17
PEG Ratio ranked lower than
100.00% of 115 companies
in the Biotechnology industry.
Industry Max: 99.55, Med: 2.02, Min: 0.06
ENTA: 1.17
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0, Med: 0, Max: 1.17
Current: 1.17
0
1.17
Current Ratio 20.68
Current Ratio ranked higher than
89.11% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ENTA: 20.68
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 8.25, Med: 20.82, Max: 36.75
Current: 20.68
8.25
36.75
Quick Ratio 20.68
Quick Ratio ranked higher than
89.20% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ENTA: 20.68
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 8.25, Med: 20.82, Max: 36.75
Current: 20.68
8.25
36.75
Days Sales Outstanding 61.82
Days Sales Outstanding ranked lower than
74.10% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ENTA: 61.82
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 2.27, Med: 23.94, Max: 118.72
Current: 61.82
2.27
118.72

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.20
3-Year Share Buyback Rate ranked higher than
89.96% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ENTA: -1.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -92.2, Med: -5.15, Max: -0.9
Current: -1.2
-92.2
-0.9

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.15
Price-to-Tangible-Book ranked higher than
52.24% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ENTA: 4.15
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.56, Med: 3.22, Max: 7.27
Current: 4.15
1.56
7.27
Price-to-Projected-FCF 1.87
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
52.85% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
ENTA: 1.87
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.29, Med: 1.97, Max: 3.3
Current: 1.87
1.29
3.3
Price-to-Median-PS-Value 0.96
Price-to-Median-PS-Value ranked lower than
71.83% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ENTA: 0.96
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.18, Med: 1.07, Max: 14.92
Current: 0.96
0.18
14.92
Price-to-Graham-Number 2.06
Price-to-Graham-Number ranked lower than
56.00% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
ENTA: 2.06
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 0.76, Med: 1.61, Max: 2.81
Current: 2.06
0.76
2.81
Earnings Yield (Joel Greenblatt) % 6.34
Earnings Yield (Greenblatt) ranked higher than
91.58% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ENTA: 6.34
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -16.8, Med: 4.85, Max: 39.2
Current: 6.34
-16.8
39.2

More Statistics

Revenue (TTM) (Mil) $ 233.98
EPS (TTM) $ 3.72
Beta 1.41
Volatility % 45.96
52-Week Range $ 64.09 - 127.77
Shares Outstanding (Mil) 19.67

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y